Compare JTAI & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JTAI | XRTX |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | Canada |
| Employees | 8 | N/A |
| Industry | Blank Checks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.3M |
| IPO Year | N/A | 2018 |
| Metric | JTAI | XRTX |
|---|---|---|
| Price | $6.28 | $2.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $80.00 | N/A |
| AVG Volume (30 Days) | 258.2K | ★ 1.7M |
| Earning Date | 05-15-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.73 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.04 | $0.35 |
| 52 Week High | $10.41 | $3.60 |
| Indicator | JTAI | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.92 | 52.02 |
| Support Level | $6.05 | $0.47 |
| Resistance Level | $9.24 | $3.03 |
| Average True Range (ATR) | 0.55 | 0.26 |
| MACD | -0.31 | -0.12 |
| Stochastic Oscillator | 12.57 | 20.20 |
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.